Valganciclovir and human herpesvirus-8

Journal of Infectious Diseases

Volumn 198, Issue 1, 2008, Pages 6-7

  Crumpacker, Clyde S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; G PROTEIN COUPLED RECEPTOR; GANCICLOVIR; PHOSPHOTRANSFERASE; PLACEBO; THYMIDINE KINASE; VALGANCICLOVIR; VIRUS PROTEIN;

BLOOD TOXICITY; CARCINOGENESIS; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG INHIBITION; EDITORIAL; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LIVER TOXICITY; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINITIS; VIRUS ONCOGENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GANCICLOVIR; HERPESVIRUS 8, HUMAN; VIRUS REPLICATION;

EID: 46349085785     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588821     Document Type: Editorial

References (15)

1. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335:721-9.
2. Hamzeh FM, Lietman PS. Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir. Antimicrob Agents Chemother 1991; 35:1818-23.
3. Hamzeh FM, Lietman PS, Gibson W, Hayward GS. Identification of the lytic origin of DNA replication in human cytomegalovirus by a novel approach utilizing ganciclovir-induced chain termination. J Virol 1990; 64:6184-95.
4. Chou S, Waldemer RH, Senters AE, et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002; 185:162-9.
5. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44:495-507.
6. Casper C, Krantz E, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008;198:23-30 (in this issue).
7. Cannon JS, Hamzeh F, Moore S, Nichols J, Ambinder RF. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 1999; 73:4786-93.
8. Gustafson EA, Schinazi RF, Fingeroth JD. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol 2000; 74:684-92.
9. Lock MJ, Thorley N, Teo J, Emery VC. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother 2002; 49:359-66.
10. Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 2004; 62:121-3.
11. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082-6.
12. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 1997; 41:2754-6.
13. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063-70.
14. Sun R, Lin S, Staskus K, et al. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 1999; 73:2232-42.
15. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391:86-9.